browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
dcd60574-b063-479a-829c-a06ed09e9219
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-21 14:25:24
Income (reported)
$50,000
Expenses (reported)
—
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

WHITMER & WORRALL, LLC

A government relations and consulting firm.

Contact
MARTIN WHITMER
Phone
+1 202-558-6000
Address
zip:20005, city:Washington, state:DC, street:1401 H Street, NW Suite 525
Client

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)

Coalition to promote lowering prescription drug prices.

State
DC
Country
US
Effective date
2023-11-01
Issues lobbied + lobbyists (4)

MMM — Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

Lobbyists:
  • MARTIN WHITMER — covered position: Deputy CoS-USDOT
  • THOMAS WORRALL
  • ERIK KOMENDANT — covered position: Legislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog Coalition

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

CPT — Copyright/Patent/Trademark

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Lobbyists:
  • MARTIN WHITMER — covered position: Deputy CoS-USDOT
  • THOMAS WORRALL
  • ERIK KOMENDANT — covered position: Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren; Policy Director, Blue Dog Coalition

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

PHA — Pharmacy

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

Lobbyists:
  • MARTIN WHITMER — covered position: Deputy CoS-USDOT
  • THOMAS WORRALL
  • ERIK KOMENDANT — covered position: Legislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog Coalition

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TAX — Taxation/Internal Revenue Code

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

Lobbyists:
  • MARTIN WHITMER — covered position: Deputy CoS-USDOT
  • THOMAS WORRALL
  • ERIK KOMENDANT — covered position: Legislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog Coalition

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.